



PHS PUBLIC ACCESS

Author manuscript

Nat Cell Biol. Author manuscript; available in PMC 2010 September 01.

Published in final edited form as:

Nat Cell Biol. 2010 March ; 12(3): 247–256. doi:10.1038/ncb2024.

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis

Li Ma^{1,2}, Jennifer Young^{1,7}, Harsha Prabhala^{3,7}, Elizabeth Pan¹, Pieter Mestdagh⁴, Daniel Muth⁵, Julie Teruya-Feldstein⁶, Ferenc Reinhardt¹, Tamer T. Onder^{1,2}, Scott Valastyan^{1,2}, Frank Westermann⁵, Frank Speleman⁴, Jo Vandesompele⁴, and Robert A. Weinberg^{1,2,8}

¹ Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA

² MIT Ludwig Center for Molecular Oncology, Cambridge, MA 02142, USA

³ Medical Scientist Training Program, University of Virginia, Charlottesville, VA 22908, USA

⁴ Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

⁵ Department of Tumor Genetics, German Cancer Center, Im Neuenheimer Feld 280, Heidelberg, Germany

⁶ Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA

Abstract

MicroRNAs (miRNAs) are increasingly implicated in regulating the malignant progression of cancer. Here we show that miR-9, the level of which is upregulated in breast cancer cells, directly targets *CDH1*, the E-cadherin-encoding mRNA, leading to increased cell motility and invasiveness. miR-9-mediated E-cadherin downregulation results in the activation of β -catenin signaling, which contributes to upregulated expression of the gene encoding vascular endothelial growth factor (VEGF); this leads, in turn, to increased tumor angiogenesis. Overexpression of miR-9 in otherwise-non-metastatic breast tumor cells enables these cells to form pulmonary micrometastases in mice. Conversely, inhibiting miR-9 using a ‘miRNA sponge’ in highly malignant cells inhibits metastasis formation. Expression of miR-9 is activated by MYC and MYCN, both of which directly bind to the *mir-9-3* locus. Significantly, in human cancers, miR-9 levels correlate with *MYCN* amplification, tumor grade, and metastatic status. These findings uncover a regulatory and signaling pathway involving a metastasis-promoting miRNA that is predicted to directly target expression of the key metastasis-suppressing protein E-cadherin.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

⁸Correspondence should be addressed to R.A.W. (weinberg@wi.mit.edu).

⁷These authors contributed equally to this work.

AUTHOR CONTRIBUTIONS

L.M. conceived the project. R.A.W. supervised research. L.M. and H.P. designed experiments. L.M., J.Y., H.P., E. P., J.T-F., and F.R. performed most of the experiments and analyzed data. P.M., D.M., F.W., F.P., and J.V. contributed MYCN and ChIP-on-chip data. T.T.O. contributed some of the constructs and shared unpublished observations. S.V. modified the miRNA sponge design for stable expression. L.M. and R.A.W. wrote the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Metastases are responsible for >90% of cancer-related mortality. These secondary growths arise as products of a multi-step process that begins when cancer cells within primary tumors break away from neighboring cells and invade through the basement membrane¹. This initial step of local invasion may frequently be triggered by contextual signals that carcinoma cells receive from the nearby stroma, causing them to undergo an epithelial-mesenchymal transition (EMT), a multi-faceted transdifferentiation program that enables tumor cells to acquire malignancy-associated phenotypes². Subsequently, metastasizing cells can enter the circulation, doing so either directly or via lymphatics. Size constraints in the microvasculature cause many of these cells to be arrested at distant tissue sites, where they may extravasate and enter the foreign tissue parenchyma. At this point, they may remain dormant or, with low efficiency, proliferate from occult micrometastases to form angiogenic, clinically detectable metastases. The absence of EMT-inducing signals in the microenvironment of distant tissues may cause such disseminated cells to revert to an epithelial phenotype via a mesenchymal-epithelial transition (MET). Much research has been focused on identifying the critical regulators of the metastatic process; these regulatory molecules include both proteins and microRNAs (miRNAs)^{3,4}.

MiRNAs are small non-coding RNA molecules that suppress gene expression by interacting with the 3' untranslated regions (UTRs) of target mRNAs. These interactions may result in either inhibition of translation of the targeted mRNAs or their degradation⁵. In an initial real-time RT-PCR-based screen for differentially expressed miRNAs, we identified three miRNAs that are most significantly upregulated in human breast cancer cell lines – miR-155, miR-9, and miR-10b⁶. The subsequent functional studies of miR-10b validated its candidacy as a mechanistically important miRNA in cancer progression, as demonstrated by experiments showing that overexpression of miR-10b in otherwise-non-metastatic breast tumors initiated tumor invasion and distant metastasis in xenograft models⁶. Subsequently, several other miRNAs, including miR-373, miR-520c, miR-335, miR-206, miR-126, miR-21, and miR-31, have also been identified as either promoters or suppressors of metastasis^{7–11}. In addition, the miR-200 family, whose role in regulating metastasis remains unclear, has emerged as a silencer of ZEB1 and ZEB2, two established EMT-inducing and metastasis-promoting transcription factors^{12,13}, thereby representing yet another set of regulators of the EMT program.

A second miRNA that stood out in our initial screen is miR-9⁶, a miRNA that is selectively expressed in neural tissues under normal conditions¹⁴ and regulates their development¹⁵. Expression of this miRNA is higher in brain tumors than in tumors of other histological types, further demonstrating a tissue-specific expression pattern¹⁶. In the context of clinical breast cancer, miR-9 has been found to be upregulated in primary tumors relative to its expression in normal mammary tissues¹⁷. Interestingly, miR-9 was recently shown to be upregulated by 1,000-fold in *c-myc*-induced mouse mammary tumors¹⁸.

In a preliminary survey, we used several computational algorithms, including the two most widely tested programs, TargetScan¹⁹ and PicTar²⁰, to search for miRNAs that target evolutionarily conserved sequences present in the *CDH1* mRNA; this survey revealed that miR-9 was the only known miRNA that was predicted to target the *CDH1* mRNA (Fig. 1a).

CDH1 encodes the epithelial cell adhesion molecule E-cadherin, a trans-membrane glycoprotein that forms the core of the adherens junctions between adjacent epithelial cells²¹. The cytoplasmic tail of E-cadherin associates with a number of intracellular proteins that link E-cadherin to the actin cytoskeleton²¹. Given its well-established function in maintaining adherens junctions, E-cadherin inactivation presumably promotes metastasis by enabling the first step of the metastatic cascade – the dissociation of carcinoma cells from one another. In addition, its loss liberates β -catenin molecules that may move into the nucleus and activate pro-metastatic genes²². The significance of E-cadherin inactivation for metastasis has been demonstrated in a variety of *in vitro* and *in vivo* models^{22–27}. Recently, we have found that E-cadherin loss in certain cell types can also trigger an EMT and a wide range of transcriptional and signaling changes that contribute to metastatic dissemination²⁷. Thus, miR-9's potential role as a suppressor of E-cadherin expression made this miRNA a strong candidate for promoting the acquisition of malignant phenotypes by carcinoma cells.

RESULTS

Effect of miR-9 on the expression of E-cadherin

To determine whether miR-9 can indeed downregulate E-cadherin expression, we stably expressed miR-9 and, as a control, miR-10b, in two epithelial cell lines (Supplementary Information, Fig. S1). Ectopic expression of miR-9, but not miR-10b, led to an EMT-like conversion in HMLE non-transformed, immortalized human mammary epithelial cells²⁸: these cells became scattered and assumed a spindle-like or star-like morphology (Fig. 1b) and displayed a 70% reduction in E-cadherin and a 5-fold increase in the mesenchymal marker vimentin (Fig. 1c). In contrast, in SUM149 human breast carcinoma cells²⁹, miR-9 downregulated E-cadherin expression by ~50% but failed to induce vimentin, other mesenchymal markers, and a fibroblastic cell morphology (Fig. 1c, and data not shown). These differences in response were intrinsic to the two cell lines rather than a consequence of different degrees of E-cadherin suppression, because knockdown of E-cadherin by >90% using small-interfering RNA (siRNA) in both cell lines caused an EMT in HMLE cells²⁷ but not in SUM149 cells (T.T.O. and R.A.W., unpublished observations). Hence, while miR-9 succeeds in suppressing E-cadherin expression in two epithelial cell lines, it only induces an EMT in one of them.

To determine whether miR-9 directly targets the *CDH1* mRNA, we performed reporter assays and found that miR-9 reduced the activity of a luciferase reporter that was fused to the wild-type 3' UTR of the *CDH1* mRNA but not to a mutant 3'UTR (Fig. 1d); the latter carried altered nucleotides that were introduced in the miR-9 'seed-pairing'¹⁹ recognition site (Fig. 1a). Hence, the observed downregulation of E-cadherin by miR-9 depends directly on a single cognate recognition site in the *CDH1* 3'UTR.

Inactivation of E-cadherin has been shown to promote cell migration and invasion in the presence or absence of an EMT²⁷. Consistent with this, we found that ectopic expression of miR-9 led to a 3- to 5-fold increase in the motility and invasiveness of both HMLE and SUM149 cells *in vitro* (Fig. 1e, f). In order to determine whether these effects depend specifically on E-cadherin suppression, we employed an expression construct that encodes the entire E-cadherin coding sequence but lacks the 3' UTR, yielding an mRNA that is

resistant to miRNA-mediated suppression. Ectopic expression of E-cadherin with this construct reduced migration and invasion in the miR-9-overexpressing cells, but not in the control cells, which have a low basal level of miR-9 (Fig. 1e, f). This suggests that following miR-9 overexpression, a resulting reduction in E-cadherin is required in order for cells to exhibit increased motility and invasiveness. However, we cannot exclude the possibility that miR-9-mediated suppression of other targets is also required for the observed effects of this miRNA on cell phenotypes.

Regulation of β -catenin signaling and VEGF expression by miR-9

Having validated E-cadherin as a miR-9 target, we next sought to determine whether miR-9-mediated E-cadherin suppression would affect intracellular signaling. Binding of Wnt ligands to their receptors results in the stabilization of β -catenin, allowing it to enter the cell nucleus, interact with the TCF/LEF family of transcription factors, and promote the transcription of genes³⁰. Independent of this, E-cadherin binds and sequesters a large pool of β -catenin at the cytoplasmic membrane, thereby preventing its nuclear translocation and its function as a component of the TCF/LEF transcription factor complex^{22,31,32}. Our previous work demonstrated that knockdown of E-cadherin in the experimentally transformed human mammary epithelial cells caused relocalization of β -catenin from adherens junctions to the cytoplasm and nucleus. Of note, this suppression of E-cadherin expression also led to a reduction of β -catenin phosphorylation by GSK-3 β through unknown regulatory mechanisms, thereby enabling the liberated β -catenin to escape proteasome-mediated degradation²⁷.

In the present work, we found that miR-9-expressing SUM149 cells exhibited both cytoplasmic and nuclear localization of β -catenin, whereas in the control SUM149 cells this protein was predominantly associated with cell-cell junctions, presumably with the cytoplasmic tails of E-cadherin molecules (Fig. 2a). Moreover, the β -catenin in miR-9-expressing cells showed a reduced level of GSK-3 β -dependent inhibitory phosphorylation (Fig. 2b) and was therefore present in a more active functional state^{27,30}.

To provide the definitive proof of β -catenin functional activation, we performed β -catenin reporter assays using both the Topflash construct with multiple TCF/LEF-binding sites in the promoter of a firefly luciferase reporter gene and the derived Fopflash construct with mutated TCF/LEF binding sites³³. These assays demonstrated that miR-9 increased β -catenin activity by >10-fold in E-cadherin-positive cells (HMLE and SUM149) but not in E-cadherin-negative human breast cancer cells (SUM159) (Fig. 2c). Of note, the basal β -catenin activity was far higher in SUM159 cells than in HMLE and SUM149 cells (Fig. 2c), which provided further indication of the inverse correlation between E-cadherin expression and β -catenin activity.

Because E-cadherin inactivation has recently been shown to promote tumor angiogenesis in genetically engineered mouse models^{22,26}, and because the pro-angiogenic factor *VEGFA* has been described as a transcriptional target gene of β -catenin^{22,34}, we used the SUM149 and SUM159 breast cancer cell lines, described above and in further detail in Supplementary Information, Fig. S2, to determine whether miR-9 would increase the levels of *VEGFA*. We found that upon miR-9 overexpression, the *VEGFA* mRNA levels increased by 3- to 4-fold

in the SUM149 cells but not in the SUM159 cells (Fig. 2d). In addition, miR-9 also suppressed E-cadherin expression and induced *VEGFA* expression by 3-fold in MCF7-RAS breast carcinoma cells (Supplementary Information, Fig. S3). Thus, the ability of miR-9 to upregulate *VEGFA* is correlated with its ability to modulate E-cadherin expression.

We undertook to determine whether the ability of miR-9 to upregulate *VEGFA* mRNA depended on its ability to downregulate E-cadherin expression and activate β -catenin-mediated transcription. We discovered that expression of either an E-cadherin siRNA or a constitutively active β -catenin (the N90 non-degradable mutant²⁷, Fig. 2e) in parental SUM149 cells was not sufficient to phenocopy the observed induction of *VEGFA* mRNA expression by miR-9; however, ectopic expression of either an E-cadherin mRNA (without 3'UTR) or a β -catenin siRNA (Fig. 2e) in miR-9-expressing SUM149 cells was indeed able to reverse the ability of miR-9 to induce *VEGFA* mRNA (Fig. 2f). These data indicate that E-cadherin downregulation and β -catenin activation are necessary but not sufficient for mediating miR-9-dependent VEGF upregulation. Stated differently, E-cadherin is a critical target of miR-9, but other functionally important miR-9 targets remain to be identified.

We next implanted miR-9-expressing or mock-infected SUM149 cells into orthotopic sites – the mammary fat pads of non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. At 12 weeks post implantation, we found an approximately 4-fold increase in the plasma level of human-specific VEGF in mice bearing miR-9-expressing SUM149 tumors compared to mice implanted with mock-infected SUM149 cells (Fig. 2g), which was accompanied by a 1.5-fold increase in primary tumor weight (Fig. 2h). We then normalized the VEGF level to the primary tumor weight for individual recipients and found that the normalized VEGF levels were still significantly higher in the miR-9 group (Fig. 2i), indicating that miR-9-expressing tumor cells do indeed secrete more VEGF *in vivo*. Finally, we found in a control experiment that miR-10b, which did not reduce E-cadherin expression in SUM149 cells (Fig. 1c), could not upregulate VEGF levels in these cells (Supplementary Information, Fig. S4).

Effects of miR-9 on tumor angiogenesis, mesenchymal traits, and the formation of micrometastases

SUM149 cells forced to express miR-9 grew more slowly *in vitro* than the corresponding control cells (Supplementary Information, Fig. S5); in contrast, *in vivo* the miR-9-expressing SUM149 tumors displayed an approximately 2-fold increase in the levels of the Ki-67 cell proliferation marker compared with those having basal levels of miR-9 expression (Fig. 3a). Hence, the observed increase in primary tumor size appeared to reflect a cell-non-autonomous effect of this miRNA, such as its ability to enhance tumor-associated angiogenesis. To address this possibility, we performed immunohistochemistry to detect expression of the MECA-32 mouse endothelial cell antigen, which should serve as a specific marker of angiogenesis. Consistent with previous observations⁶, the control SUM149 tumors displayed only low levels of staining. In stark contrast, miR-9-expressing SUM149 tumors exhibited a >10-fold increase in the density of intratumoral microvessels (Fig. 3b), which is in consonance with the observed higher levels of VEGF secreted by these tumor cells.

In fact, an even more robust vessel formation was observed at the outer edges of these miR-9-expressing tumors than in the intratumoral regions (Supplementary Information, Fig. S6a). Of additional interest, some of the cells within the lumina of vessels at the tumor edge were nucleated and were positive for cytokeratin expression, providing evidence for miR-9-induced intravasation of carcinoma cells (Supplementary Information, Fig. S6a, b). Although the great majority of carcinoma cells within the miR-9-expressing and control tumors exhibited similar morphology (Fig. 3a, b), the carcinoma cells located near vessels at the tumor edge (Supplementary Information, Fig. S6a) were cytologically different from the bulk populations of carcinoma cells (Fig. 3a, b) in the miR-9-overexpressing tumors. We reasoned that these cytologically distinctive cells were either stromal cells of host origin or, alternatively, carcinoma cells undergoing an EMT *in vivo*.

To distinguish between these possibilities, we performed immunostaining with antibodies reactive with E-cadherin and human vimentin. As expected, the miR-9-expressing human tumor xenografts had weaker E-cadherin staining than control tumors (data not shown). More strikingly, a significant number of carcinoma cells at the edges of the miR-9-expressing tumors exhibited strong human vimentin staining, while intratumoral regions only displayed occasional human vimentin-positive cells (Fig. 3c). The control tumors, which expressed lower levels of miR-9, were essentially vimentin-negative (Fig. 3c). Moreover, as anticipated, mouse fibroblasts in the tumor stroma were completely negative for human vimentin (Fig. 3c), demonstrating that the observed vimentin-positive cells did indeed derive from implanted human carcinoma cells. Because miR-9-induced vimentin expression in cultured HMLE cells but not in SUM149 cells (Fig. 1c), we propose that this miRNA can induce an EMT in a cell type- and context-dependent manner, and that in certain cell types, such as SUM149 carcinoma cells, miR-9 sensitizes cells to EMT-inducing signals emanating from the tumor microenvironment rather than eliciting an EMT on its own.

SUM149 cells have been reported to exhibit little, if any, metastatic ability^{6,35}. Indeed, we observed that mouse hosts bearing control SUM149 primary tumors were essentially free of lung micrometastases except for one mouse, which showed a single micrometastatic cluster that was immunostained by the AE1/AE3 anti-cytokeratin antibodies at 12 weeks after cancer cell implantation (Fig. 3d). In stark contrast, the lungs of mice implanted in the mammary fat pads with miR-9-overexpressing SUM149 cells exhibited clusters of dense hyperchromatic cells that were positive for cytokeratins, as demonstrated by both histological examination (Fig. 3e) and AE1/AE3 immunostaining (Fig. 3f). On average, we found ~14 micrometastases per 5- μ m section (Fig. 3d). This provided direct evidence that miR-9 operates as a pro-metastatic miRNA.

Effects of miR-9 silencing on metastasis

We also wished to determine whether miR-9 expression is required for metastasis formation by cancer cells that are naturally highly malignant. To address this, we used 'miRNA sponges'^{11,36} to stably knock down miR-9 in the highly metastatic 4T1 mouse mammary tumor cells that naturally express a very high level of miR-9 (data not shown). A 'miRNA sponge' is a construct encoding an mRNA (e.g., the *gfp* mRNA) that contains in its 3'UTR

multiple tandem binding sites for a miRNA of interest³⁶. We assessed the level of functional knockdown of miR-9 by a reporter assay, in which the predicted miR-9 binding site was introduced into the 3'UTR of a luciferase reporter gene⁶, and found that infection of 4T1 cells with the miR-9 sponge caused a >2-fold increase in luciferase activity compared with the control sponge (Fig. 4a); this suggested that a greater than 50% inhibition of the actions of miR-9 had been achieved by the miR-9 sponge. We then implanted the infected 4T1 cells into the mammary fat pads of syngeneic immunocompetent Balb/c mice. Four weeks later, mice were moribund due to primary tumor burdens in both groups, and no difference in primary tumor size was observed between the 4T1 tumors expressing a control sponge and those expressing the miR-9 sponge (Fig. 4b). Examination of lungs revealed an average of 35 visible metastases in mice implanted with 4T1 cells expressing the control sponge (Fig. 4c, d); in contrast, an approximately 50% reduction in lung metastases (average: 17 visible metastases per mouse) was observed in mice bearing 4T1 tumors expressing the miR-9 sponge (Fig. 4c–e). Thus, inhibition of miR-9 can suppress metastasis formation by otherwise-highly malignant cancer cells.

Activation of miR-9 expression by MYC/MYCN

We undertook to determine how miR-9 expression is regulated. Consistent with our previous findings⁶, immortalized, non-transformed HMLE cells naturally expressed a low level of miR-9, whereas the breast cancer cell lines examined expressed higher levels of this miRNA (Fig. 5a). Interestingly, a correlation between *RAS* status and miR-9 levels was observed in various cell lines; for instance, both the MCF7-*RAS* human breast cancer cells, which express an introduced, activated *RAS* oncoprotein (H-RASV12)³⁷, and the MDA-MB-231 human breast cancer cells, which contain an activating *K-RAS*, codon 12 mutation³⁸, showed significantly higher miR-9 levels than did the HMLE and MCF7 cells, both of which lack an activated *RAS* oncogene³⁸ (Fig. 5a). Of note, relative to miRNA expression in normal mammary tissues, miR-9 stood out as the most significantly upregulated miRNA in mammary tumors arising in the MMTV-*c-myc* transgenic mice¹⁸. We found this to be particularly interesting, because *RAS* can potentiate *MYC* activity to promote tumor angiogenesis³⁹. Moreover, oncogenic *RAS* is capable of inducing *VEGF* expression⁴⁰.

Responding to these various observations, we were particularly interested in the actions of *MYC*, because this transcription factor has been shown to directly regulate expression of a diverse set of miRNAs (e.g., the oncogenic miR-17-92 miRNA cluster) that contribute in one way or another to tumorigenesis^{41–43}. For this reason, we ectopically expressed *MYC* in HMLE cells and found that a 4-fold increase in *MYC* expression level resulted in an approximately 3-fold increase in the level of mature miR-9 (Fig. 5b). miR-9 can be generated by the processing of any of three primary transcripts encoded by three distinct genes. Among the three encoding genes, the transcription of *mir-9-3* is upregulated most strongly (3.9-fold, Fig. 5b) by the *MYC* transcription factor.

Another *MYC* gene family member, *N-MYC* (*MYCN*), is frequently amplified in neuroblastomas. Operating as transcription factors, *MYC* and *MYCN* share a common set of target genes and are, from this perspective, functionally interchangeable. To evaluate whether *MYCN* can also upregulate miR-9, we measured its expression in a *MYCN*-

inducible model system, SHEP-MYCN-ER⁴². Upon 4-hydroxy-tamoxifen (4-OHT)-mediated activation of the MYCN-ER fusion protein, miR-9 expression level was increased by 4-fold, which was comparable to the increase in the expression of the miR-17-92 positive control, whose expression is known to be activated by MYCN through direct promoter binding⁴⁴ (Fig. 5c).

To determine whether MYC and MYCN regulate the expression of miR-9 by binding directly to the corresponding genomic sequences, we performed genome-wide ChIP-on-chip experiments using the Kelly and SJ-NB-12 neuroblastoma cells, which express high levels of endogenous MYCN and MYC, respectively, due in both cases to gene amplification. We observed that the endogenously expressed MYCN and MYC proteins bound directly to a conserved CpG island region encompassing canonical MYC binding sites (CACGTG) in the *mir-9-3* locus; this was observed in both the Kelly and SJ-NB-12 neuroblastoma cells (Fig. 5d).

The association of chromatin-bound MYC with H3K4Me3 (a mark of activated chromatin) at MYC-regulated genes has been described previously⁴⁵. Indeed, we found that MYC binding at the *mir-9-3* locus was associated with elevated H3K4me3 binding (Supplementary Information, Fig. S7). Although we also observed a peak for MYC binding at *mir-9-1* and *mir-9-2* loci, respectively, these two regions exhibited low occupancy by H3K4me3 and relatively high occupancy by H3K27me3 (a mark of repressed chromatin, data not shown). Hence, among the three miR-9-encoding genes, the transcription of *mir-9-3* is the most responsive to transcriptional activation by MYC/MYCN.

Recently, others have identified candidate transcriptional start sites (TSSs) and promoters of the great majority of human and mouse miRNA genes⁴⁶. They exploited yet other findings that histone H3 is trimethylated at lysine 4 (H3K4me3) at the TSSs and promoters of most genes (>90%) in the genome. This study identified position 87712233 of chromosome 15 as the putative human *mir-9-3* TSS⁴⁶. In the present study, we observed co-occupancy by H3K4me3 and MYC of this putative *mir-9-3* TSS region (close to position 87712000; Supplementary Information, Fig. S7), as well as of a region upstream of this putative *mir-9-3* TSS (near position 87708500, where a canonical E-box is located; Supplementary Information, Fig. S7). Hence, the regions in which we observed MYC binding appear to encompass the *mir-9-3* TSS and promoter, providing further evidence of transcriptional regulation of the *mir-9-3* gene by MYC.

Correlation of miR-9 with *MYCN* amplification, tumor grade, and metastatic status in human cancers

To extend our analysis to clinical cancers, we measured the expression of miR-9 in a cohort of 45 neuroblastoma tumor samples. Twenty-two tumors exhibited normal *MYCN* copy number and were classified as Stage 1 (n = 10), Stage 2 (n = 6) or Stage 3 (n = 6) neuroblastomas. Twenty-three tumors were classified as Stage 4 neuroblastomas and these showed *MYCN* gene amplification. Compared to tumors with normal *MYCN* copy number, tumors that exhibited an amplification of the *MYCN* gene showed a 2.5-fold upregulation of miR-9 expression ($p = 9 \times 10^{-4}$, Fig. 6a). The observed increase of miR-9 expression was similar to that of the miRNAs belonging to the miR-17-92 cluster (average miR-17-92 fold

increase = 2.6, Supplementary Information, Fig. S8), which was previously shown to be upregulated in MYC/MYCN-overexpressing tumors^{42, 47}.

We also examined miR-9 levels in clinical breast cancers. Consistent with our expression analyses of cultured cell lines, miR-9 levels were significantly elevated in primary breast tumors from patients with diagnosed metastases compared to those from metastasis-free patients (fold increase = 4.33, $p = 0.007$, Fig. 6b).

DISCUSSION

Model for miR-9-mediated pathway in cancer metastasis

Our findings identify miR-9 as a pro-metastatic miRNA and a negative regulator of the key metastasis suppressor, E-cadherin. On the basis of our results, we propose that the MYC and MYCN oncoproteins, acting on the *mir-9-3* locus, cause activation of miR-9 expression in tumor cells. The resulting miR-9 miRNA can suppress the expression of E-cadherin, resulting in the promotion of carcinoma cell motility and invasiveness and, in addition, causing the activation of β -catenin signaling; the latter, in turn, contributes to elevated expression of *VEGFA*, leading to induction of tumor-associated angiogenesis. Ultimately, both increased cell motility and invasiveness, as well as enhanced angiogenesis, can contribute to metastasis formation (Fig. 6c). Since E-cadherin downregulation and β -catenin activation appear to be necessary but not sufficient for mediating miR-9-dependent VEGF upregulation (Fig. 2f), yet other miR-9 targets must also operate to enable VEGF induction by this miRNA (Fig. 6c). Indeed, the E-cadherin-independent roles of miR-9 in tumor cells warrant further investigation.

Paradoxically, a recent study proposed that miR-9 might be a candidate metastasis-suppressing miRNA, based on the observation that miR-9-encoding gene promoters, as well as the promoters of genes encoding two other miRNAs (miR-34b/c and miR-148a), were methylated in a relatively large fraction of primary tumors present in patients with lymph node metastases; in contrast, only a small fraction of primary tumors from patients without lymph node metastases exhibited this promoter methylation, while the status of distant metastases of these tumors was not determined⁴⁸. Importantly, because the miR-9 expression levels in these tumors were not determined, it remains unclear whether there was a correlation between miR-9 gene methylation status and miR-9 miRNA levels. Furthermore, when ectopically expressed in several highly malignant cells, miR-34b/c and miR-148a suppressed metastasis formation, while miR-9 did not⁴⁸.

Yet other lines of evidence indicate that miR-9 is positively associated with malignancy of human cancers. Some have demonstrated that miR-9 expression is significantly upregulated in both clinical breast cancers¹⁷ and in *c-myc*-induced mouse mammary tumors¹⁸. We have found that miR-9 is upregulated in various breast cancer cell lines compared with non-transformed mammary epithelial cell lines, and that metastatic breast cancer cells express even higher miR-9 levels than non-metastatic tumor cells. miR-9 is also upregulated in metastatic breast tumors compared to non-metastatic breast tumors from patients (Fig. 6b). These results suggest that methylation of the promoters of miR-9 genes reported in the cited study⁴⁸ does not indicate a wider role of this miRNA in inhibiting metastasis.

miR-9 expression and EMT

In contrast to miR-10b, which is specifically upregulated in metastatic cancer cells⁶, miR-9 expression is upregulated in both metastatic and non-metastatic tumor cells relative to non-transformed cells. These observations, together with the fact that miR-9 expression can be increased by the actions of MYC and MYCN oncoproteins, cause us to propose that miR-9 expression is often induced at earlier stages of multi-step tumor progression when elevated MYC and MYCN expression is already apparent⁴⁹ but before tumors become actively invasive and metastatic.

Can miR-9, acting on its own, initiate the EMT program? In the SUM149 carcinoma cells, the partial reduction of E-cadherin levels mediated by this miRNA does not directly induce an EMT *in vitro* (Fig. 1c and data not shown); instead, it seems to sensitize these tumor cells to EMT-inducing signals arising from the tumor microenvironment. This leads to the acquisition by carcinoma cells of mesenchymal traits late in tumor progression (Fig. 3c), which could in turn contribute to metastatic dissemination.

A contrasting response was observed in HMLE cells, in which we did indeed observe an EMT-like conversion resulting from overexpression of miR-9 (Fig. 1b, c). One possibility is that miR-9 might induce an EMT in a cell type-dependent and context-dependent manner; for example, HMLE cells have undergone functional inactivation of both p53 and Rb, which might prime these cells for induction of an EMT. Alternatively, the apparent ability of miR-9 to induce an EMT in HMLE cells might be explained by selection for a pre-existing rare mesenchymal subpopulation present within this particular cell line⁵⁰. Unlike the HMLE cell line, the SUM149 cell line used in this study does not contain a detectable mesenchymal subpopulation, based on the absence of detectable levels of the mesenchymal marker vimentin (Figure 1c) and on FACS profiles (data not shown). For this reason, the selection mechanism, if it ever occurs, applies to HMLE cells but not to SUM149 cells, and the conclusions drawn from SUM149 experiments are unaffected.

Inactivation of the key metastasis suppressor E-cadherin can occur via a variety of distinct mechanisms, such as promoter hypermethylation and the actions of various EMT-inducing transcription factors. Our findings identify an additional mechanism for downregulating E-cadherin and indicate that elevated expression of the miR-9 miRNA contributes to EMT and metastasis in some and possibly many human tumors.

METHODS

Methods and any associated references are available in the online version of the paper.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Johannes Schulte, Martin Eilers, Rosa Noguera, Margaret Ebert, and Phillip Sharp for providing tumor samples and reagents; the Histology Core Lab at MIT and MSKCC for assistance with sectioning and IHC; and members of the Weinberg Lab for useful discussions. L.M. is a recipient of a Life Sciences Research Foundation

Fellowship, a Margaret and Herman Sokol Award, and an NIH Pathway to Independence Award (K99/R00). J.Y. and E.P. are supported by a Howard Hughes Medical Institute Undergraduate Fellowship. J.T-F. is supported by the MSKCC Cancer Core Grant. T.T.O. and S.V. are recipients of a U.S. Department of Defense Breast Cancer Research Program Predoctoral Fellowship. R.A.W. is an American Cancer Society Research Professor and a Daniel K. Ludwig Cancer Research Professor. This research is supported by an NIH grant to R.A.W. and the Ludwig Center for Molecular Oncology at MIT.

References

1. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nat Rev Cancer*. 2003; 3:453–8. [PubMed: 12778135]
2. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer*. 2002; 2:442–54. [PubMed: 12189386]
3. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs--the micro steering wheel of tumour metastases. *Nat Rev Cancer*. 2009; 9:293–302. [PubMed: 19262572]
4. Ma L, Weinberg RA. Micromanagers of malignancy: role of microRNAs in regulating metastasis. *Trends Genet*. 2008; 24:448–56. [PubMed: 18674843]
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116:281–97. [PubMed: 14744438]
6. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature*. 2007; 449:682–8. [PubMed: 17898713]
7. Huang Q, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. *Nat Cell Biol*. 2008; 10:202–10. [PubMed: 18193036]
8. Tavazoie SF, et al. Endogenous human microRNAs that suppress breast cancer metastasis. *Nature*. 2008; 451:147–52. [PubMed: 18185580]
9. Asangani IA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. *Oncogene*. 2008; 27:2128–36. [PubMed: 17968323]
10. Zhu S, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. *Cell Res*. 2008; 18:350–9. [PubMed: 18270520]
11. Valastyan S, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell*. 2009; 137:1032–46. [PubMed: 19524507]
12. Gregory PA, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol*. 2008; 10:593–601. [PubMed: 18376396]
13. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev*. 2008; 22:894–907. [PubMed: 18381893]
14. Deo M, Yu JY, Chung KH, Tippens M, Turner DL. Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. *Dev Dyn*. 2006; 235:2538–48. [PubMed: 16736490]
15. Leucht C, et al. MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary. *Nat Neurosci*. 2008; 11:641–648. [PubMed: 18454145]
16. Nass D, et al. MiR-92b and miR-9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors. *Brain Pathol*. 2008
17. Iorio MV, et al. MicroRNA gene expression deregulation in human breast cancer. *Cancer Res*. 2005; 65:7065–70. [PubMed: 16103053]
18. Sun Y, et al. Expression profile of microRNAs in c-Myc induced mouse mammary tumors. *Breast Cancer Res Treat*. 2008
19. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*. 2005; 120:15–20. [PubMed: 15652477]
20. Krek A, et al. Combinatorial microRNA target predictions. *Nat Genet*. 2005; 37:495–500. [PubMed: 15806104]

21. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. *Nat Rev Mol Cell Biol.* 2005; 6:622–34. [PubMed: 16025097]
22. Ceteci F, et al. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. *Cancer Cell.* 2007; 12:145–59. [PubMed: 17692806]
23. Frixen UH, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. *J Cell Biol.* 1991; 113:173–85. [PubMed: 2007622]
24. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell.* 1991; 66:107–19. [PubMed: 2070412]
25. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. *Nature.* 1998; 392:190–3. [PubMed: 9515965]
26. Derksen PW, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. *Cancer Cell.* 2006; 10:437–49. [PubMed: 17097565]
27. Onder TT, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Res.* 2008; 68:3645–54. [PubMed: 18483246]
28. Elenbaas B, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. *Genes Dev.* 2001; 15:50–65. [PubMed: 11156605]
29. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. *Cancer Res.* 1993; 53:627–35. [PubMed: 8425198]
30. Nusse R. Wnt signaling in disease and in development. *Cell Res.* 2005; 15:28–32. [PubMed: 15686623]
31. Wong AS, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. *J Cell Biol.* 2003; 161:1191–203. [PubMed: 12810698]
32. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. *J Cell Biol.* 2001; 153:1049–60. [PubMed: 11381089]
33. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. *Curr Biol.* 2003; 13:680–5. [PubMed: 12699626]
34. Skurk C, et al. Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. *Circ Res.* 2005; 96:308–18. [PubMed: 15662032]
35. Kuperwasser C, et al. A mouse model of human breast cancer metastasis to human bone. *Cancer Res.* 2005; 65:6130–8. [PubMed: 16024614]
36. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. *Nat Methods.* 2007; 4:721–6. [PubMed: 17694064]
37. Orimo A, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell.* 2005; 121:335–48. [PubMed: 15882617]
38. von Lintig FC, et al. Ras activation in human breast cancer. *Breast Cancer Res Treat.* 2000; 62:51–62. [PubMed: 10989985]
39. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. *Cancer Cell.* 2003; 3:219–31. [PubMed: 12676581]
40. Rak J, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. *Cancer Res.* 1995; 55:4575–80. [PubMed: 7553632]
41. Chang TC, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. *Nat Genet.* 2008; 40:43–50. [PubMed: 18066065]
42. Schulte JH, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. *Int J Cancer.* 2008; 122:699–704. [PubMed: 17943719]

43. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. *Nature*. 2005; 435:839–43. [PubMed: 15944709]
44. Fontana L, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. *PLoS ONE*. 2008; 3:e2236. [PubMed: 18493594]
45. Guccione E, et al. Myc-binding-site recognition in the human genome is determined by chromatin context. *Nat Cell Biol*. 2006; 8:764–70. [PubMed: 16767079]
46. Marson A, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell*. 2008; 134:521–33. [PubMed: 18692474]
47. Northcott PA, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. *Cancer Res*. 2009; 69:3249–55. [PubMed: 19351822]
48. Lujambio A, et al. A microRNA DNA methylation signature for human cancer metastasis. *Proc Natl Acad Sci U S A*. 2008; 105:13556–61. [PubMed: 18768788]
49. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. *Oncogene*. 1999; 18:3004–16. [PubMed: 10378696]
50. Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*. 2008; 133:704–15. [PubMed: 18485877]
51. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. *Science*. 2004; 303:83–6. [PubMed: 14657504]
52. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. *Nucleic Acids Res*. 2005; 33:1290–7. [PubMed: 15741182]
53. Stewart SA, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. *Rna*. 2003; 9:493–501. [PubMed: 12649500]
54. Westermann F, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. *Genome Biol*. 2008; 9:R150. [PubMed: 18851746]
55. Mestdagh P, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. *Oncogene*. 2009
56. Brodeur GM, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. *J Clin Oncol*. 1988; 6:1874–81. [PubMed: 3199170]
57. Mestdagh P, et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. *Nucleic Acids Res*. 2008; 36:e143. [PubMed: 18940866]
58. Mestdagh P, et al. A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biol*. 2009; 10:R64. [PubMed: 19531210]




Figure 1. miR-9 directly targets *CDH1* and increases cell motility and invasiveness

(a) Left panel: predicted duplex formation between human *CDH1* 3'UTR and miR-9. Right panel: sequence of the miR-9 binding site within the *CDH1* 3'UTR of human (hs), mouse (mm), and rat (rn).

(b) Phase contrast images of HMLE cells infected with the miR-9-expressing, miR-10b-expressing, or empty vector. Cells were plated on 10 cm dishes at the same density (1×10^6 cells in 10 ml medium). Two days after plating, images were taken and cells were then counted (cell numbers are shown in parentheses). Magnification: x200.

(c) Immunoblotting of E-cadherin and vimentin in HMLE and SUM149 cells infected with the miR-9-expressing, miR-10b-expressing, or empty vector.

(d) Luciferase activity of the wild-type or mutant *CDH1* 3'UTR reporter gene in SUM149 cells infected with the miR-9-expressing or empty vector.

(e, f) Transwell migration assay and Matrigel invasion assay of miR-9-transduced or mock-infected HMLE (e) and SUM149 (f) cells with or without ectopic expression of E-cadherin. A representative experiment is shown in triplicate along with s.e.m. in d–f.




Figure 2. miR-9 increases VEGF levels in an E-cadherin- and β -catenin-dependent manner
(a) Immunofluorescence staining of β -catenin (red) in mock-infected or miR-9-expressing SUM149 cells demonstrates differential localization. Right panels are the overlay of β -catenin and nuclear 4',6-diamidino-2-phenylindole (DAPI; blue) staining of the same field. White arrows indicate cells positive for nuclear β -catenin. Insets: blow-up images of particular cells. Magnification: x200.
(b) Immunoblotting of phospho- β -catenin (Ser33/37/Thr41, GSK-3 β phosphorylation sites) and β -catenin in SUM149 cells infected with the miR-9-expressing or empty vector.
(c) Topflash reporter assay in HMLE, SUM149, and SUM159 cells infected with the miR-9-expressing or empty vector.
(d) Real-time RT-PCR of total *VEGFA* mRNA in SUM149 and SUM159 cells infected with the miR-9-expressing or empty vector.
(e) Immunoblotting of E-cadherin and β -catenin in SUM149 cells infected with E-cadherin siRNA (si-Ecad) or Δ N90 β -catenin (Δ N90), and in SUM149-miR-9 cells infected with E-cadherin (Ecad) or β -catenin siRNA (si- β cat). Vec: the pLKO-puro vector with a scrambled sequence that does not target any mRNA.

(f) Real-time RT-PCR of total *VEGFA* mRNA in the same cells described in e. A representative experiment is shown in triplicate along with s.e.m. in **c**, **d** and **f**.
(g-i) Plasma levels of VEGF (**g**), primary tumor weight (**h**), and normalized VEGF levels (**i**) in mice that received orthotopic injection of miR-9-transduced or mock-infected SUM149 cells, at week 12 after transplantation. Data are presented as mean \pm s.e.m. (n = 8 mice per group).




Figure 3. miR-9 induces angiogenesis, mesenchymal marker expression, and metastasis of the SUM149 epithelial tumors

(a, b) Left panels: Ki-67- (a) and MECA-32-stained sections (b) of primary mammary tumors formed by mock-infected or miR-9-transduced SUM149 cells, at week 12 after orthotopic transplantation. The circle and arrow indicate pyknotic nuclei. Magnification: x200 for Ki-67; x400 for MECA-32. Right panels: counting of Ki-67-positive cells (a) and intratumoral vessels (the number of microvessels per field, b). Data are presented as mean \pm s.e.m. (we counted three fields per section and analyzed four mice per group).

(c) Human-specific vimentin staining of primary mammary tumors formed by mock-infected or miR-9-transduced SUM149 cells, at week 12 after orthotopic transplantation. Both intratumoral regions (center) and tumor-stroma interfaces (edge) are shown. Magnification: x200. n = 3 mice per group were analyzed for vimentin.

(d) Numbers of lung micrometastases per section in individual mice that received orthotopic injection of miR-9-transduced or mock-infected SUM149 cells, at week 12 after transplantation. Data are presented as mean \pm s.e.m. (each data point represents a different mouse; n = 5 mice per group).

(e, f) H&E- **(e)** and AE1/AE3 (a cocktail of two distinct anti-cytokeratin monoclonal antibodies, **f**)-stained sections of lungs isolated from mice that received orthotopic injection of miR-9-transduced or mock-infected SUM149 cells, at week 12 after transplantation. Circles indicate clusters of micrometastatic cells. Arrows indicate normal bronchial epithelium. Magnification: x200 in left columns; x600 in right columns.




Figure 4. Inhibiting miR-9 suppresses metastasis

(a) Enhanced activity of miR-9-regulated reporter by infection of 4T1 cells with the miR-9 sponge. A representative experiment is shown in triplicate along with s.e.m.

(b) Primary tumor weight in Balb/c mice that received orthotopic injection of 4T1 cells infected with the miR-9 sponge or control sponge, at 4 weeks after transplantation.

(c) Bright field imaging and H&E staining of lungs isolated from mice that received orthotopic injection of 4T1 cells infected with the miR-9 sponge or control sponge, at 4 weeks after transplantation. Arrows indicate metastatic nodules. Magnification: x8 for bright field imaging; x40 for H&E staining.

(d, e) Numbers of visible lung metastases (d) and metastasis index (= number of metastases/primary tumor weight, e) in mice that received orthotopic injection of 4T1 cells infected with the miR-9 or control sponge, at 4 weeks after transplantation. Data in b, d and e are presented as mean \pm s.e.m. (n = 8 mice per group).




Figure 5. miR-9 expression is activated by MYC/MYCN

(a) Real-time RT-PCR of miR-9 in HMLE, MCF7, MCF7-RAS, and MDA-MB-231 cells.

(b) Real-time RT-PCR of *MYC*, mature miR-9, *mir-9-1*, *mir-9-2*, and *mir-9-3* in mock-infected or MYC-transduced HMLE cells.

(c) Mature miRNA expression in SH-EP-MYCN-ER cells upon MYCN induction with 4-OHT, 48 h after treatment. MiRNA expression values were rescaled relative to the control (no 4-OHT). The miR-17-92 expression value represents the expression of miR-20a, a miRNA residing within the miR-17-92 cluster representative for miR-17-92 expression.

Data in a–c are presented as mean \pm s.e.m. of triplicate samples.

(d) ChIP-on-chip data showing occupancy of the *mir-9-3* genomic sequence by MYCN and MYC in Kelly (*MYCN*-amplified) and SJ-NB-12 (*MYC*-amplified) neuroblastoma cells, respectively. The genomic positions for probes and their enrichment ratios are displayed on the X and Y axes, respectively. Smoothed local enrichment ratios are given for either MYCN or MYC at the *mir-9-3* locus in Kelly and SJ-NB-12 cells. The red line indicates median enrichment ratio for MYCN or MYC versus input as calculated of all probes for chromosome 15.




Figure 6. miR-9 levels correlate with *MYCN* amplification and metastatic status in human cancers

(a) Expression of mature miR-9 in *MYCN*-normal copy ($n = 22$) and *MYCN*-amplified ($n = 23$) neuroblastoma tumor samples.

(b) Expression of mature miR-9 in primary breast tumor samples from metastasis-free and metastasis-positive patients. Data in **a** and **b** are presented as mean \pm s.e.m.

(c) Model for miR-9-mediated pathway in cancer metastasis.